Serina Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026, reporting a net loss of $7,906 thousand for the three months ended September 30, 2026.

Key Highlights

  • Net loss of $7,906 thousand was attributable to Serina Therapeutics, Inc. for the three months ended September 30, 2026, compared to $4,585 thousand for the same period in 2025, according to the filing.
  • Cash and cash equivalents of $19,403 thousand at September 30, 2026, up from $3,056 thousand at December 31, 2025, as reported on the balance sheet.
  • Total revenues of $125 thousand for the nine months ended September 30, 2026, consisting entirely of contract revenues, versus $130 thousand in grant revenues for the same period in 2025.
  • Research and development expenses of $11,642 thousand for the nine months ended September 30, 2026, compared to $9,754 thousand for the nine months ended September 30, 2025.
  • Common shares outstanding increased to 26,407 thousand at September 30, 2026, from 10,767 thousand at December 31, 2025, with common stock authorized shares expanded from 40,000 thousand to 125,000 thousand.
  • Accumulated deficit reached $84,660 thousand at September 30, 2026, up from $63,500 thousand at December 31, 2025.
  • Total stockholders' equity of $13,919 thousand at September 30, 2026, compared to a stockholders' deficit of $(37) thousand at December 31, 2025.

Serina Therapeutics Reports Third-Quarter 2026 Financial Results

According to the filing, Serina Therapeutics, Inc. (NYSE American:SER) reported total operating expenses of $7,986 thousand for the three months ended September 30, 2026, comprised of $4,627 thousand in research and development expenses and $3,359 thousand in general and administrative expenses. For the nine months ended September 30, 2026, total operating expenses were $21,050 thousand. The company reported a loss from operations of $7,861 thousand for the third quarter of 2026, compared to $6,392 thousand for the third quarter of 2025.

The filing disclosed that total other expense, net, was $(45) thousand for the three months ended September 30, 2026, reflecting interest expense of $(204) thousand and a change in fair value of warrants of $58 thousand. For the nine months ended September 30, 2026, the filing noted a loss on extinguishment of financial commitment assets and contingent warrants, net, of $(1,616) thousand and a change in fair value of tranche liability of $1,377 thousand. Net loss per share attributable to Serina common stockholders, basic and diluted, was $(0.31) for the three months ended September 30, 2026, based on weighted-average common shares outstanding of 25,413 thousand.

The company's balance sheet showed total assets of $21,873 thousand at September 30, 2026, compared to $6,951 thousand at December 31, 2025. The filing reported that Series A convertible preferred stock, which had 965 thousand shares issued and outstanding with a liquidation preference of $5,000 thousand at December 31, 2025, had zero shares issued and outstanding at September 30, 2026. The convertible note, net, stood at $3,173 thousand at September 30, 2026. The number of shares of common stock outstanding as of November 10, 2026 was 26,569,458, according to the filing's cover page.

What Was Disclosed

Serina Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $7,906 thousand for the quarter, a significant increase in cash to $19,403 thousand, and a shift from stockholders' deficit to positive equity of $13,919 thousand since December 31, 2025.